Investor Relations

High-growth medical device company and market leader within single-use endoscopy

Latest news

18

May. 2026

Transactions under Ambu’s share buyback program

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.

During the program, Ambu will repurchase shares for a total amount of up to DKK 300m from 6 May 2026 until no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.

The following transactions have been made under the program from 11 May 2026 to 13 May 2026:

 Number of sharesAverage purchase price, DKKTransaction value, DKK
Accumulated under the program after last announcement316,49162.134819,665,105
2026.05.11100,00062.39656,239,646
2026.05.1212,13261.5977747,303
2026.05.13120,00062.59407,511,277
Accumulated under the program548,62362.271134,163,332


After the above disclosed transactions DKK 265,836,668 remains to be repurchased. Ambu now owns 4,743,781 treasury shares, corresponding to 1.8% of the share capital.

 

Download the full company announcement here.

11

May. 2026

Transactions under Ambu’s share buyback program

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.                                                                                            

During the program, Ambu will repurchase shares for a total amount of up to DKK 300m from 6 May 2026 until no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.

The following transactions have been made under the program from 6 May 2026 to 8 May 2026:

 Number of sharesAverage purchase price, DKKTransaction value, DKK
Accumulated under the program after last announcement00.00000
2026.05.06250,00062.124615,531,150
2026.05.0747,00062.27642,926,991
2026.05.0819,49161.92491,206,978
Accumulated under the program316,49162.134819,665,105


After the above disclosed transactions DKK 280,334,895 remains to be repurchased. Ambu now owns 4,511,649 treasury shares, corresponding to 1.5% of the share capital.

Download the company announcement here.

07

May. 2026

Reporting of transactions made by persons discharging managerial responsibilities (no. 13)

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

This attached document discloses the data of the transactions made by Executive Management.

 
Read the full company announcement here.

Ambu presented at the JP Morgan 2026 healthcare conference

Download the PDF presentation delivered by Ambu CEO Britt Meelby Jensen

 

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Upcoming events

26

Aug. 2026

Earnings release Q3 2025/26

30

Sep. 2026

End of fiscal year 2025/26

05

Nov. 2026

Annual report 2025/26

News from Ambu

Sign up and receive financial news and company announcements from Ambu

Sign up

 

keyboard_arrow_up